Ad
related to: ocular hypertension clinical trial- Discover Patient Types
See If Your Patients' Conditions
Qualify Them For Treatment.
- View Tolerability Info
Learn About Treatment Tolerability
For A Glaucoma Treatment.
- ECP Resources & Videos
View Resources & Videos To Help You
Treat Your Glaucoma Patients.
- Patient Savings Available
Eligible Patients May Pay As Little
As $25 Copay For A 90-Day Supply.
- Discover Patient Types
Search results
Results from the WOW.Com Content Network
Ocular hypertension is the presence of elevated fluid pressure inside the eye (intraocular pressure), ... In 2002, a clinical trial in the United States, ...
The US Food and Drug Administration (FDA) approved latanoprostene bunod based on evidence from two clinical trials that enrolled 840 participants with open angle glaucoma or ocular hypertension. [4] The trials evaluated the benefits and side effects of latanoprostene bunod. [4]
The Company's lead product candidate, trabodenoson (formerly known as INO-8875), is being evaluated for the treatment of elevated intraocular pressure associated with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). Trabodenoson has completed Phase 1, 2, and 3 clinical trials in subjects with OHT and POAG.
About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology.
In people with ocular hypertension (IOP ≥21 mm Hg) including open-angle glaucoma, treatment with latanoprost reduced IOP levels by 22 to 39% over 1 to 12 months’ treatment. Latanoprost is more effective than timolol 0.5% twice daily in 3 of 4 large (n = 163 to 267) randomised, double-blind trials. Latanoprost demonstrated a stable long-term ...
A 12-week prospective, randomized, double-blinded study in 371 glaucoma and ocular hypertension patients with inadequate IOP control on monotherapy compared the efficacy and safety of 0.2% brimonidine tartrate/0.5% timolol fixed combination twice daily with the concomitant use of 0.2% brimonidine tartrate twice daily and timolol 0.5% twice ...
Bimatoprost/timolol, sold under the brand name Ganfort, is a medication for the treatment of certain conditions involving high pressure in the eyes, specifically open angle glaucoma and ocular hypertension. [1] [3] It is available as eye drops. [1] [3] It was approved for medical use in the European Union in May 2006. [3]
Ripasudil has been proven to have additional medical uses aside from reducing IOP and alleviating symptoms of glaucoma and ocular hypertension. For example, in March 2016 the drug was shown to promote corneal endothelial cell (CEC) proliferation in cultured human cells as well as wound healing and endothelium regeneration in a rabbit wound ...
Ad
related to: ocular hypertension clinical trial